English 
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
Description
Obstructive sleep apnea (OSA)—also referred to as obstructive sleep apnea-hypopnea—is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep. These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
Obstructive sleep apnea– OSA Epidemiology
OSA remains significantly under-recognized, as only 20% of cases in the United States according to the AASM and 20% of cases globally have been properly diagnosed. We hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of OSA cases are due to demographic shifts.
The reported rates of psychiatric diagnosis among modafinil users do seem to be higher than the 18.3% (of adults in the USA) stated in the 2016 National (USA) Survey on Drug Use and Mental Health. As per the survey, overall, modafinil was perceived by users as being safe. Modafinil users reported higher levels of illicit drug use and psychiatric diagnosis than would be expected from population-based data. More frequent reported modafinil use was associated with higher numbers of perceived benefits whilst reported frequency of use was not associated with the number of perceived risks, We are expecting 18% of the OSA patients on this therapy in the base year and will subsequently decline as the new therapies entering into the market.
Obstructive sleep apnea Market Forecast
The Obstructive Sleep Apnea (OSA) therapy market is expected to experience high growth throughout our study period, increasing from $XX million in 2018 to $XX billion in 2032, representing 17.78% annual growth. Primary drivers of this growth will be uptake of the therapies Modafinil/Armodafinil (Takeda), Solriamfetol/Sunosi (Jazz Pharmaceuticals), Dronabinol (RespireRx Pharmaceuticals), BAY2586116 (Bayer), AD109 (Apnimed), AD036 (Apnimed), AD128 (Apnimed) and THX-110 (Therapix bio), predominantly in the United States.
There are no specific treatments for the treatment Obstructive Sleep Apnea (OSA) and current care treatment for OSA involves CPAP (Continuous Positive Airway Pressure) is which is the leading device therapy for Obstructive Sleep Apnea (OSA). This treatment involves the patient wearing a mask that connects through a hose to a bedside air pump. Although the therapy has demonstrated improvements in patient-reported sleep quality and reductions in daytime sleepiness, around 35% – 65% are non-CPAP compliant. Patients complain of problems including mask discomfort, mask leakage, pressure intolerance, skin irritation, nasal congestion, nasal drying, nosebleeds, claustrophobia, and lack of intimacy. The CPAP therapy accounts for the 70% of the device-treated OSA population share.
Obstructive Sleep Apnea (OSA) Market Size by Country Mellalta Meets
Report Highlights
- Obstructive sleep apnea Current Market Trends
- Obstructive sleep apnea Current & Forecasted Cases across the G7 Countries
- Obstructive sleep apnea Market Opportunities And Sales Potential for Agents
- Obstructive sleep apnea Patient-based Market Forecast to 2032
- Obstructive sleep apnea Untapped Business Opportunities
- Obstructive sleep apnea Product Positioning Vis-a-vis Competitors’ Products
- Obstructive sleep apnea KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- Obstructive Sleep Apnea Disease Background
- Obstructive Sleep Apnea Definition
- Symptoms
- Risk Factor
- Diagnosis
- Epidemiology Estimated and Forecast to 2032
- Epidemiology Research Method & Data Sources Used
- Incident Cases of Obstructive Sleep Apnea in the United States 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in the United States 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United States 2022-2032
- Incident Cases of Obstructive Sleep Apnea in Germany 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in Germany 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Germany 2022-2032
- Incident Cases of Obstructive Sleep Apnea in France 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in France 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in France 2022-2032
- Incident Cases of Obstructive Sleep Apnea in Italy 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in Italy 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Italy 2022-2032
- Incident Cases of Obstructive Sleep Apnea in Spain 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in Spain 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Spain 2022-2032
- Incident of Obstructive Sleep Apnea in the United Kingdom 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in the United Kingdom 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United Kingdom 2022-2032
- Incident Cases of Obstructive Sleep Apnea in Japan 2022-2032
- Cases of Obstructive Sleep Apnea by OSA by severity in Japan 2022-2032
- Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Japan 2022-2032
- Epidemiology Research Method & Data Sources Used
- Current Unmet Needs in Obstructive Sleep Apnea
- Current Treatment Paradigm
- Treatment guidelines for Obstructive Sleep Apnea
- Current Therapies for Obstructive Sleep Apnea
- Emerging Therapies Chapters
- Dronabinol (RespireRx Pharmaceuticals)
- BAY2586116 (Bayer)
- AD109 (Apnimed)
- AD036 (Apnimed)
- AD128 (Apnimed)
- THX-110 (Therapix bio)
- AD182 and AD504 (Apnimed)
- Lemborexant (Eisai)
- MK-7264 (Merck)
- Seltorexant (Janssen)
- ACT-541468 (Idorsia)
- SAS0421 (Apnimed)
- OSA Product Positioning
- Key Competitors
- Total Market Forecast
- Key Summary Findings
- G7 total Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- G7 total Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- Key Summary Findings
- Market Forecast by Country
- United States
- United States Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- United States Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- Germany Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- France
- France Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- France Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- Italy Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- Spain Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- United Kingdom Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Obstructive Sleep Apnea 2022-2032 (USD Million)
- Japan Market for Obstructive Sleep Apnea by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers & Barriers
- Appendix
- About Mellalta Meets
Sample Enquiry
Related products
-
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2022-2032 study period, adding an estimated value to a total more than $1 billion market by 2032
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.